Biotech Values

[DewDiligence]

ARYX was off 24% (Wed AH vs Tue close) on loss of PG as a partner for ATI-7505:

http://biz.yahoo.com/bw/080702/20080702005984.html

…despite the company’s cheesy attempt to soften the blow with data from a QTc study on a different compound (ATI-7505):

http://biz.yahoo.com/bw/080702/20080702005979.html

p.s. My main interest in ARYX is its “next-generation warfarin” compound called ATI-5923 (#msg-30170392).


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”